B
Brian Gazzard
Researcher at National Health Service
Publications - 22
Citations - 4386
Brian Gazzard is an academic researcher from National Health Service. The author has contributed to research in topics: Viral load & Efavirenz. The author has an hindex of 9, co-authored 22 publications receiving 4275 citations. Previous affiliations of Brian Gazzard include Queen Mary University of London & University of Connecticut.
Papers
More filters
Journal ArticleDOI
CD4+ count-guided interruption of antiretroviral treatment.
Wafaa El-Sadr,Wafaa El-Sadr,Jens D Lundgren,James D. Neaton,Fred M. Gordin,Dominic Abrams,Roberto C. Arduino,Abdel Babiker,William J. Burman,Nathan Clumeck,Calvin J. Cohen,David V. Cohn,David A. Cooper,Janet Darbyshire,Sean Emery,Gerd Fätkenheuer,Brian Gazzard,Birgit Grund,Jennifer F Hoy,Karin L. Klingman,M. H. Losso,Norman Markowitz,Jacquie Neuhaus,Andrew N. Phillips,Claire Rappoport +24 more
TL;DR: Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load.
Journal ArticleDOI
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
Brian Gazzard,Jane Anderson,Abdel Babiker,Marta Boffito,Gary Brook,Gary Brough,Duncan Churchill,Ben Cromarty,Satyajit Das,Martin Fisher,Andrew L. Freedman,Anna Maria Geretti,Margaret A. Johnson,Saye Khoo,Clifford Leen,Devaki Nair,Barry Peters,Andrew N. Phillips,Deenan Pillay,Anton Pozniak,John P. Walsh,Ed Wilkins,Ian S. Williams,Matthew Williams,M Youle +24 more
TL;DR: The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information since the last iteration and all the peer-reviewed publications and important, potentially treatment-changing abstracts from the last 2 years have been reviewed.
Journal ArticleDOI
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Patrick Yeni,Scott M. Hammer,Charles C. J. Carpenter,David A. Cooper,Margaret A. Fischl,Jose M. Gatell,Brian Gazzard,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Mauro Schechter,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Paul A. Volberding +17 more
TL;DR: Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease, however, the optimal time to initiate therapy remains imprecisely defined.
Journal ArticleDOI
Loss of Discrete Memory B Cell Subsets Is Associated with Impaired Immunization Responses in HIV-1 Infection and May Be a Risk Factor for Invasive Pneumococcal Disease
Melanie Hart,Alan Steel,Sally Clark,Graeme Moyle,Mark Nelson,Don C. Henderson,Robert Wilson,Frances Gotch,Brian Gazzard,Peter Kelleher +9 more
TL;DR: It is demonstrated that defects in B cell memory subsets are associated with impaired humoral immune responses in HIV-1 patients who are receiving antiretroviral therapy and may be a contributory factor to the increased risk of invasive pneumococcal infection observed in HIV -1 infection.
Journal ArticleDOI
Brief Communication: Rituximab in HIV-associated Multicentric Castleman Disease
Mark Bower,Thomas Powles,Sarah Williams,Tom Newsom Davis,Mark Atkins,Silvia Montoto,Chloe Orkin,Andrew J. Webb,Martin Fisher,Mark Nelson,Brian Gazzard,Justin Stebbing,Peter Kelleher +12 more
TL;DR: The efficacy and safety of rituximab as initial monotherapy and correlate clinical findings with immune subset, plasma cytokine, and HIV and KSHV virologic variables are investigated.